PlainPharmaWatch

CMS Open Payments · Program Year 2024

Telix Pharmaceuticals

Telix Pharmaceuticals reported $1,342,549.80 across General Payments, Research, and Ownership to 2,920 physicians and teaching hospitals across 3,009 transactions.

See the rankings → How this is sourced
$1.3M Above-median payer
All-tracks total
3,009 Top quartile volume
Transactions
2,920 Top quartile reach
Recipients
+$236.3K
General Payments vs PY2023

Telix Pharmaceuticals reported $1,342,549.80 across all CMS Open Payments tracks (General + Research + Ownership) to 2,920 physicians and teaching hospitals in Program Year 2024 - ranking #549 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $753,888.30, averaging $459.78 per recipient.

How Telix Pharmaceuticals's $1.3M all-tracks total breaks down

Telix Pharmaceuticals's payment reach score

Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.

Overall reach score

F

37/100

Total payments

F

22/100

Transaction volume

F

32/100

Physician reach

F

32/100

Payment type diversity

D

63/100

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer telix-pharmaceuticals Telix Pharmaceuticals

$1.3M · #549/1,925 · 0.0% industry · PY2024

  • TOT $1.3M
  • RANK #549
  • SHARE 0.0%
  • TXN 3,009
  • RCP 2,920
  • CAT 5
  • GEN $753.9K
  • ΔGEN +$236.3K
  • TOP1 35.4%
  • PY 2024

Volume peers

Nearest volume peer: Vericel Corporation ($1.3M)

Biofrontera Bioscience GmbH$1.3MVericel Corporation$1.3MTelix Pharmaceuticals (this)$1.3MLeadiant Biosciences, Inc.$1.3MSurmodics, Inc.$1.3M
All-tracks payment totals near Telix Pharmaceuticals (CMS Open Payments PY2024)

Telix Pharmaceuticals sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Telix Pharmaceuticals's CMS-reported General Payments increased by $236.3K (+45.6%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: TELIX PHARMACEUTICALSPY2023: TELIX PHARMACEUTICALSPY2024: Telix Pharmaceuticals. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$517.6KPY2024$753.9K
PY2023
$517,608.47
PY2024
$753,888.30

What the Data Shows for Telix Pharmaceuticals

Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Telix Pharmaceuticals, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.

168 transactions worth $481.7K make "Consulting Fee" the top general-payment category in the 5-category breakdown below, 63.9% of General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Telix Pharmaceuticals made 5 types of general payments. "Consulting Fee" is the largest category at $481.7K, 63.9% of General Payments.

Telix Pharmaceuticals reports 5 general-payment categories - the top three are Consulting Fee (63.9%), Food and Beverage (15.1%), and Travel and Lodging (12.4%). The remaining 2 categories make up 8.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How Telix Pharmaceuticals divides its payments

Ranked by total dollars reported per category

1. Consulting Fee$481.7K2. Food and Beverage$114.1K3. Travel and Lodging$93.8K4. Grant$43.3K5. Education$21.0K
Payment Type Amount Transactions
Consulting Fee $481.7K 168
Food and Beverage $114.1K 2,577
Travel and Lodging $93.8K 163
Grant $43.3K 8
Education $21.0K 4

Recipient Concentration in General Payments

The five largest recipient relationships account for $362,591.17 (48.1%) of $753,888.30 in this company's General Payments records across 1,702 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Telix Pharmaceuticals

The five named recipients with the highest reported General Payments from this company

Jaideep Sohi$266.8KUmesh Oza$31.0KDelphine Chen$21.8KUniversity of Washington Med…$21.6KAmir Lavaf$21.4K
  1. 1

    Jaideep Sohi

    $266,753.65 across 118 reported transactions

  2. 2

    Umesh Oza

    $31,001.87 across 26 reported transactions

  3. 3

    Delphine Chen

    $21,778.76 across 5 reported transactions

  4. 4

    University of Washington Med Ctr

    $21,648.00 across 4 reported transactions

  5. 5

    Amir Lavaf

    $21,408.89 across 15 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Spend vs. Concentration

Telix Pharmaceuticals ranks #549 of 1,925 by total payments (top 29% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #910 of 1,838 by HHI (top 50% most concentrated), a wider distribution than most similarly sized payers.

026.553.079.5106.01306.91324.013411358.01375.1Total payments ($M)Concentration (HHI, 0-10,000)
Telix Pharmaceuticals (highlighted) among its 12 nearest HHI-concentration neighbors, Program Year 2024. Dashed lines mark this neighborhood's median payment total and median HHI. Hover a point for the company name. Source: company_concentration (CMS Open Payments general-payment recipients).
View all 12 companies in this HHI neighborhood as a list

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Telix Pharmaceuticals's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Telix Pharmaceuticals.

CMP Pharma, Inc.

HHI 1325

Alphatec Spine, Inc

HHI 1321

Piramal Critical Care

HHI 1328

Surgical Specialties Corporation (us), Inc. (dba Corza Medical)

HHI 1318

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Telix Pharmaceuticals.

Showing 6 of 1,924 companies with CMS-reported payment data.

Put this to use

Telix Pharmaceuticals ranks #549 of 1,925 by all-tracks total payments, led by "Consulting Fee".

Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Telix Pharmaceuticals's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.